卖什么
Discovering drugs that target the DNA regulome
商业模式拆解
买家：谁掌握预算？
未核实Discovery and research leads at biotech/pharma companies (access form lists Biotech/Pharma, Academic, Non-profit).
触发点：什么让他们现在购买？
Targets with no 3D structure or known pocket (flexible or disordered proteins) that structure-based tools cannot handle.
工作流：什么输入变成什么输出？
Input a protein sequence, screen billions of compounds with Ptarmigan-1, predict proteome-wide selectivity and site-level engagement, then validate in living cells with MARMOT profiling.
经济账：省了什么，怎么收费？
Model access and discovery collaborations / profiling services; claims 3.4B compounds x 20,431 proteins top-ligand retrieval in 20 H100 GPU-hours and roughly 5,000x throughput vs Boltz-2. Commercial terms not published.
渠道：怎么接触到客户？
Request-access form for commercial discovery collaborations and academic access; no self-serve pricing shown.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.